VCP
AQST icon

Verus Capital Partners’s Aquestive Therapeutics AQST Stock Holding History

Verus Capital Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Buy
51,625
+21,225
+70% +$86.1K 0.01% 427
2025
Q4 		$196K Buy
30,400
+13,600
+81% +$84.7K 0.01% 430
2025
Q3 		$93.9K Buy
+16,800
New +$72.6K 0.01% 411

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verus Capital Partners's AQST Position: Q1 2026 in Review

Verus Capital Partners increased its Aquestive Therapeutics (AQST) stake by 70% in Q1 2026, buying an estimated $86.1K and bringing the position to 51,625 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #427.

Verus Capital Partners first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Verus Capital Partners held 51,625 shares of Aquestive Therapeutics worth $214K as of Q1 2026.
  • Verus Capital Partners bought 21,225 Aquestive Therapeutics shares in Q1 2026, an estimated $86.1K.
  • Aquestive Therapeutics made up 0.01% of Verus Capital Partners's portfolio in Q1 2026, its #427 holding.
  • Verus Capital Partners first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.